Results 81 to 90 of about 5,353 (192)

Adult Erythroblastic Sarcoma With PCM1::JAK2 Fusion and a Novel NOP10::NUTM1 Fusion Complicated by Secondary HLH

Journal of Cellular and Molecular Medicine, Volume 30, Issue 14, July 2026.
ABSTRACT Erythroblastic sarcoma is a rare and aggressive hematologic malignancy presenting as a mass‐forming extramedullary proliferation of immature erythroid cells. Myeloid/lymphoid neoplasms with JAK2 rearrangement, most often PCM1::JAK2, may show eosinophilia, myelofibrosis, and expansion of immature erythroid precursors.
Tong Ge, Dong Kuang, Xia Mao, Songya Liu, Jin Wang, Qilin Ao, Min Xiao   +6 more
wiley   +1 more source

Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells

, 2020
Acute myeloid leukemia (AML) withFLT3-ITD mutations (FLT3-ITDmut) remains a therapeutic challenge, with a still high relapse rate, despite targeted treatment with tyrosine kinase inhibitors.
Del Principe, Maria Ilaria, Divona, Mariadomenica, Nardozza, Anna Maria, Alfonso, Valentina, Battistini, Luca, Travaglini, Serena, Venditti, Adriano, Fiori, Valentina, Fabiani, Emiliano, De Bardi, Marco, Barragan, Eva, Lo-Coco, Francesco, Forghieri, Fabio, Cerretti, Raffaella, Consalvo, Maria Irno, Arcese, William, Neri, Benedetta, Marchesi, Francesco, Voso, Maria Teresa, Ottone, Tiziana, Dominici, Sabrina, Guerrera, Gisella, Angelini, Daniela Francesca, Paterno, Giovangiacinto, Lavorgna, Serena   +24 more
core   +1 more source

Image_1_Leukemia Stem Cell Frequency at Diagnosis Correlates With Measurable/Minimal Residual Disease and Impacts Survival in Adult Acute Myeloid Leukemia.tif

, 2022
Acute myeloid leukemia (AML) is a heterogenous disease in which the initiation and maintenance of the malignant clone is blamed on a rare population of leukemia stem cells (LSCs).
Nahla M. Elsharkawy (12372586), Azza M. Kamel (12372583), Marwa Hanafi (12372592), Randa A. Osman (12372598), Eman Z. Kandeel (12372589), Mohammed Samra (12372595)   +5 more
core   +1 more source

Supplementary Table 5 from A Leukemia-Associated CD34/CD123/CD25/CD99⁺ Immunophenotype Identifies <i>FLT3</i>-Mutated Clones in Acute Myeloid Leukemia

, 2023
<p>Supplementary Table 5. Longitudinal analysis of FLT3-ITDs using patient-specific RQPCR in four AML patients.</p>
Francesco Lo-Coco, Luca Battistini, Adriano Venditti, Sergio Amadori, Giorgio Bernardi, Giovanna Borsellino, Maria Irno Consalvo, Nélida I. Noguera, Mariadomenica Divona, Luca Maurillo, Francesca Gargano, Marco De Bardi, Francesco Buccisano, Michela Cittadini, Serena Lavorgna, Gisella Guerrera, Tiziana Ottone, Daniela F. Angelini   +17 more
openaire   +1 more source

Reprogramming Antitumor Immunity: NK Cell Strategies to Navigate the Immunosuppressive Tumor Microenvironment

Advanced Science, Volume 13, Issue 35, 24 June 2026.
ABSTRACT Tumor immune escape is a major barrier to durable cancer immunotherapy, as advanced malignancies create a tumor microenvironment (TME) that preferentially exhausts and disables T cell responses. While most approved cell therapies are T cell‐based, this limitation motivates the exploration of an alternative effector cell platform.
Tereza Kochs, Pranay Nath, Alice Chen, Rizwan Romee, Andreia Maia   +4 more
wiley   +1 more source

Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells

International audienceAbstract Chimeric antigen receptor (CAR) T cells express an extracellular domain consisting of a single-chain fragment variable (scFv) targeting a surface tumor-associated antigen. scFv selection should involve safety profiling with
Anna, François, Robinet, Eric, Fredon, Maxime, Mantion, Charles-Frédéric, Adotévi, Olivier, Chevrier, Sandrine, Deconinck, Eric, Caumartin, Julien, Biichlé, Sabeha, Godet, Yann, Garnache-Ottou, Francine, Bonnefoy, Francis, Daguidau, Etienne, Loustau, Maria, Galaine, Jeanne, Angelot-Delettre, Fanny, Boidot, Romain, Gonçalves-Venturelli, Mathieu, Saas, Philippe, Roussel, Xavier, Seffar, Evan, Poussard, Margaux, Renosi, Florian, Bôle-Richard, Elodie   +23 more
core   +1 more source

Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC

, 2014
Data source: Supplementary information, http://www.nature.com/leu Link to a related website: https://www.nature.com/articles/leu2014128.pdf, Open Access via UnpaywallAcute myeloid leukemia (AML) is a biologically heterogeneous group of related diseases ...
Vairo, G., Ghosh, S., Roberts, A, He, S, Nash, A., Panousis, C., Lee, E, He, S., Lock, R., Lock, RB ; https://orcid.org/, Biondo, M, Roberts, A., Lock, R et al, Braley, H., Braley, H, Busfield, S, Thomas, D, Biondo, M., Wong, M., Ramshaw, H., Wong, M, Ramshaw, H, Busfield, S., Lopez, A., Ghosh, S, Fabri, L, Fabri, L., Thomas, D., Panousis, C, Lee, E., Vairo, G   +30 more
core   +1 more source

Image_2_Leukemia Stem Cell Frequency at Diagnosis Correlates With Measurable/Minimal Residual Disease and Impacts Survival in Adult Acute Myeloid Leukemia.tif

, 2022
Acute myeloid leukemia (AML) is a heterogenous disease in which the initiation and maintenance of the malignant clone is blamed on a rare population of leukemia stem cells (LSCs).
Nahla M. Elsharkawy (12372586), Azza M. Kamel (12372583), Marwa Hanafi (12372592), Randa A. Osman (12372598), Eman Z. Kandeel (12372589), Mohammed Samra (12372595)   +5 more
core   +1 more source

CD34+ CD38- subpopulation without CD123 and CD44 is responsible for LSC and correlated with imbalance of immune cell subsets in AML [PDF]

BIOCELL, 2022
QIANSHAN TAO, QING ZHANG, HUIPING WANG, HAO XIAO, MEI ZHOU, LINLIN LIU, HUI QIN, JIYU WANG, FURUN AN, ZHIMIN ZHAI, YI DONG   +10 more
openaire   +1 more source

COMIP‐002: 27‐color flow cytometry for measurable residual disease detection in B‐cell lymphoblastic leukemia

Cytometry Part B: Clinical Cytometry, Volume 110, Issue 5, Page 321-325, September 2026.
Ryan C. Shean, Patricia Davis, Jeffery Jacobsen, David P. Ng   +3 more
wiley   +1 more source